Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 4/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.45 |
| ▸ | HTR2B | P41595 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833273 | 0.85 | CDK2 (0.47) | MCL1CDK2CMA1CTSGHTR2C | |
| SCHEMBL20119869 | 0.84 | HTR2C (0.63) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL21392216 | 0.84 | CMA1 (0.64) | CDK2CMA1CTSGHTR2CHTR2B | |
| SCHEMBL18509797 | 0.83 | CMA1 (0.47) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL20120027 | 0.83 | CMA1 (0.47) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL18509674 | 0.83 | CMA1 (0.47) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL20935266 | 0.82 | CMA1 (0.45) | MCL1CDK2CMA1CTSGHTR2C | |
| SCHEMBL18509808 | 0.82 | PTGER1 (0.50) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL18509716 | 0.81 | CMA1 (0.46) | CMA1CTSGHTR2CHTR2BHTR2A | |
| SCHEMBL18509795 | 0.81 | HTR2C (0.50) | CMA1CTSGHTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078467-B2 | Highly active self-sufficient nitration biocatalysts | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190292527-A1 | HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2016134145-A9 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078467-B2 | Highly active self-sufficient nitration biocatalysts | POR, CYP4F3, CBR3 | MCL1 3164/4885CDK2 3721/4885CMA1 1371/4885 |
| US-20190292527-A1 | HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS | POR, CYP4F3, CBR3 | MCL1 3164/4885CDK2 3721/4885CMA1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.